Evolution of 3-(4-hydroxyphenyl)indoline-2-one As a Scaffold for Potent and Selective Anticancer Activity

Overview

Journal RSC Med Chem

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2022 Jul 11

PMID 35814932

Authors

Matthew W Boudreau

Paul J Hergenrother

Affiliations

Soon will be listed here.

Abstract

Development of targeted anticancer modalities has prompted a new era in cancer treatment that is notably different from the age of radical surgery and highly toxic chemotherapy. Behind each effective compound is a rich and complex history from first identification of chemical matter, detailed optimization, and mechanistic investigations, ultimately leading to exciting molecules for drug development. Herein we review the history and on-going journey of one such anticancer scaffold, the 3-(4-hydroxyphenyl)indoline-2-ones. With humble beginnings in 19th century Bavaria, we review this scaffold's synthetic history and anticancer optimization, including its recent demonstration of tumor eradication of drug-resistant, estrogen receptor-positive breast cancer. Compounds containing the 3-(4-hydroxyphenyl)indoline-2-one pharmacophore are emerging as intriguing candidates for the treatment of cancer.

Citing Articles

Single Dose of a Small Molecule Leads to Complete Regressions of Large Breast Tumors in Mice.

Mulligan M, Boudreau M, Bouwens B, Lee Y, Carrell H, Zhu J ACS Cent Sci. 2025; 11(2):228-238.

PMID: 40028352 PMC: 11869136. DOI: 10.1021/acscentsci.4c01628.

Identification of 3-((4-Hydroxyphenyl)amino)propanoic Acid Derivatives as Anticancer Candidates with Promising Antioxidant Properties.

Kavaliauskas P, Grybaite B, Sapijanskaite-Banevic B, Anusevicius K, Jonuskiene I, Stankeviciene R Molecules. 2024; 29(13).

PMID: 38999077 PMC: 11243380. DOI: 10.3390/molecules29133125.

References

Puyang X, Furman C, Zheng G, Wu Z, Banka D, Aithal K . Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα and ERα Breast Cancer. Cancer Discov. 2018; 8(9):1176-1193. DOI: 10.1158/2159-8290.CD-17-1229. View

Singh G, Desta Z . Isatins as privileged molecules in design and synthesis of spiro-fused cyclic frameworks. Chem Rev. 2012; 112(11):6104-55. DOI: 10.1021/cr300135y. View

Ardini E, Menichincheri M, Banfi P, Bosotti R, De Ponti C, Pulci R . Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications. Mol Cancer Ther. 2016; 15(4):628-39. DOI: 10.1158/1535-7163.MCT-15-0758. View

Jaskulska A, Janecka A, Gach-Janczak K . Thapsigargin-From Traditional Medicine to Anticancer Drug. Int J Mol Sci. 2020; 22(1). PMC: 7792614. DOI: 10.3390/ijms22010004. View

Hanan E, Liang J, Wang X, Blake R, Blaquiere N, Staben S . Monomeric Targeted Protein Degraders. J Med Chem. 2020; 63(20):11330-11361. DOI: 10.1021/acs.jmedchem.0c00093. View

. Laxative drug products for over-the-counter human use. Food and Drug Administration, HHS. Final rule. Fed Regist. 1999; 64(19):4535-40. View

Freedy A, Liau B . Discovering new biology with drug-resistance alleles. Nat Chem Biol. 2021; 17(12):1219-1229. PMC: 9530778. DOI: 10.1038/s41589-021-00865-9. View

Satish G, Polu A, Ramar T, Ilangovan A . Iodine-Mediated C-H Functionalization of sp, sp(2), and sp(3) Carbon: A Unified Multisubstrate Domino Approach for Isatin Synthesis. J Org Chem. 2015; 80(10):5167-75. DOI: 10.1021/acs.joc.5b00581. View

Chu I, Arnaout A, Loiseau S, Sun J, Seth A, McMahon C . Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer. J Clin Invest. 2007; 117(8):2205-15. PMC: 1906730. DOI: 10.1172/JCI21739. View

10.

Uddin M, Reignier S, Coulter T, Montalbetti C, Granas C, Butcher S . Syntheses and antiproliferative evaluation of oxyphenisatin derivatives. Bioorg Med Chem Lett. 2007; 17(10):2854-7. DOI: 10.1016/j.bmcl.2007.02.060. View

11.

Welsh A, Lannin D, Young G, Sherman M, Figueroa J, Henry N . Cytoplasmic estrogen receptor in breast cancer. Clin Cancer Res. 2011; 18(1):118-26. PMC: 3263348. DOI: 10.1158/1078-0432.CCR-11-1236. View

12.

Wanitschke R . Intestinal filtration as a consequence of increased mucosal hydraulic permeability. A new concept for laxative action. Klin Wochenschr. 1980; 58(6):267-78. DOI: 10.1007/BF01476568. View

13.

Schwartz H, Richards R, Fontana R, Joyce A, Honeywell M, Lee M . Drug GRADE: An Integrated Analysis of Population Growth and Cell Death Reveals Drug-Specific and Cancer Subtype-Specific Response Profiles. Cell Rep. 2020; 31(12):107800. PMC: 7394473. DOI: 10.1016/j.celrep.2020.107800. View

14.

Toft D, Shyamala G, Gorski J . A receptor molecule for estrogens: studies using a cell-free system. Proc Natl Acad Sci U S A. 1967; 57(6):1740-3. PMC: 224541. DOI: 10.1073/pnas.57.6.1740. View

15.

Dunnick J, Hailey J . Phenolphthalein exposure causes multiple carcinogenic effects in experimental model systems. Cancer Res. 1996; 56(21):4922-6. View

16.

Abderrahman B, Maximov P, Curpan R, Fanning S, Hanspal J, Fan P . Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer. Mol Cancer Ther. 2020; 20(1):11-25. PMC: 7790886. DOI: 10.1158/1535-7163.MCT-20-0563. View

17.

Bekes M, Langley D, Crews C . PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022; 21(3):181-200. PMC: 8765495. DOI: 10.1038/s41573-021-00371-6. View

18.

Castles C, Fuqua S, Klotz D, Hill S . Expression of a constitutively active estrogen receptor variant in the estrogen receptor-negative BT-20 human breast cancer cell line. Cancer Res. 1993; 53(24):5934-9. View

19.

McHARDY G, BALART L . Jaundice and oxyphenisatin. JAMA. 1970; 211(1):83-5. View

20.

Johnson T, Gallego R, Edwards M . Lipophilic Efficiency as an Important Metric in Drug Design. J Med Chem. 2018; 61(15):6401-6420. DOI: 10.1021/acs.jmedchem.8b00077. View